WVE – Technical Market Research
WVE cratered 49.6% on INLIGHT dose-response data. RSI at 19.41, volume 15x average — is this capitulation or the beginning of further downside? Rachel Kensington lays out the levels.
Published March 27, 2026 | Equity | WVE
Rachel Kensington
Senior Equity Analyst · Blue Ocean Trading Solutions
Technical Overview
Let me be direct: the tape is screaming at us right now, and what it's screaming is that something fundamental has shifted for Wave Life Sciences. On March 26, WVE opened at $5.36 and traded down to an intraday low of $5.02 — a single-session collapse of nearly 50% on volume of 50.2 million shares, roughly 15.5x its 30-day average of 3.24 million. That's not selling. That's capitulation on a clinical data read.
